Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Greggs (GRG) by Ben McPoland in The Motley Fool
- Sell Inspired (INSE) by Steve Moore in ShareProphets
- Neutral Schroders (SDR) by JP Morgan
- Sell Jaywing (JWNG) by Steve Moore in ShareProphets
- Sell Jubilee Metals Group (JLP) by Tom Winnifrith in ShareProphets
- Sell Jubilee Metals Group (JLP) by Steve Moore in ShareProphets
- Sell Tribe Technology (TRYB) by Steve Moore in ShareProphets
- Outperform Hollywood Bowl Group (BOWL) by RBC Capital
- Buy JD Sports Fashion (JD.) by Harvey Jones in The Motley Fool
- Hold Legal & General Group (LGEN) by Harvey Jones in The Motley Fool
- Sell Gelion (GELN) by Steve Moore in ShareProphets
- Buy GSK (GSK) by Harvey Jones in The Motley Fool
- Neutral Synthomer (SYNT) by UBS
- Neutral Carvana Co Class A (0A79) by UBS
- Equal Weight United Utilities Group (UU.) by Barclays
- Overweight Workspace Group (WKP) by Barclays
- Equal Weight Safestore Holdings (SAFE) by Barclays
- Equal Weight Severn Trent (SVT) by Barclays
- Overweight Pennon Group (PNN) by Barclays
- Overweight Land Securities Group (LAND) by Barclays
Faron Pharmaceuticals Oy (DI) (FARN) Share Price
Health Care Sector
NOTE: This is based on 3 open tips for Faron Pharmaceuticals Oy (DI) (FARN)
| Latest Bid : 160.00p | Latest Ask : 170.00p |
| High Today : 168.50p | Low Today : 163.12p |
| This Years High : 324.00p | This Years Low : 92.50p |
| Volume : 15,167 | MKT Cap : £171.6M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Faron Pharmaceuticals Oy (DI) (FARN) Overview
We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.Faron Pharmaceuticals Oy (DI) (FARN) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Under Review | Panmure Gordon | Premium Only | 2020-02-07 09:15:00 07/02/2020 | – |
| Buy | Panmure Gordon | Premium Only | 2017-09-07 08:30:00 07/09/2017 | 0.69% |
| Buy | Panmure Gordon | Premium Only | 2017-02-20 14:40:00 20/02/2017 | -37.67% |
Faron Pharmaceuticals Oy (DI) (FARN) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 160.00p | Latest Ask : 170.00p |
| High Today : 168.50p | Low Today : 163.12p |
| This Years High : 324.00p | This Years Low : 92.50p |
| Volume : 15,167 | MKT Cap : £171.6M |
Faron Pharmaceuticals Oy (DI) Overview
We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Faron Pharmaceuticals Oy (DI) Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Under Review | Panmure Gordon | Premium Only | 2020-02-07 09:15:00 07/02/2020 | – |
| Buy | Panmure Gordon | Premium Only | 2017-09-07 08:30:00 07/09/2017 | 0.69% |
| Buy | Panmure Gordon | Premium Only | 2017-02-20 14:40:00 20/02/2017 | -37.67% |